Loading...

BNTC BENITEC BIOPHARMA INC Management Changes 8-K Filing

BNTC

BNTC

BENITEC BIOPHARMA INC

(BNTC)

2025 8-K

Annual Meeting Results

Financial Update

Stock Offering Announcement

Board Appointment & FDA News

Financial Update

Financial Statement Correct...

Product Expansion

Financial Statements

Registration Agreement

Clinical Study Results

Clinical Trial Data

Financial Results

Management Change

Management Changes

Preferred Stock Issuance

Annual Meeting Results

Financial Results

Bonus Approvals

Clinical Trial Update

Warrant Exercises

Financial Results

Stockholder Meeting

Clinical Trial Data Announc...

Appointment of Director

Earnings Reports

Private Placement

Clinical Trial Data Announc...

Grants of Executive Stock O...

Earnings Reports

Annual Meeting Approval

Earnings Reports

Departure of Directors or C...

Compliance with Nasdaq List...

Financial Results Announcement

Salary Increases

Public Offering

Stock Options Grant

Earnings Reports

Earnings Reports

External Links:

On November 3, 2025, Benitec Biopharma Inc. announced the appointment of Dr. Sharon Mates to its Board and revealed that the FDA granted Fast Track Designation to its treatment BB-301 for Oculopharyngeal Muscular Dystrophy.

AI Assistant

BENITEC BIOPHARMA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.